|
gptkbp:instanceOf
|
gptkb:drug
dopamine antagonist
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A03FA01
|
|
gptkbp:brand
|
gptkb:Maxolon
gptkb:Reglan
|
|
gptkbp:CASNumber
|
364-62-5
|
|
gptkbp:chemicalClass
|
benzamide
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
epilepsy
gastrointestinal hemorrhage
mechanical bowel obstruction
|
|
gptkbp:discoveredBy
|
gptkb:Charles_Laville
gptkb:Justin-Besançon
|
|
gptkbp:discoveredIn
|
1964
|
|
gptkbp:eliminationHalfLife
|
5–6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C14H22ClN3O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Metoclopramide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
5-HT3 receptor antagonist
5-HT4 receptor agonist
|
|
gptkbp:meltingPoint
|
147–150 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
A (Australia)
|
|
gptkbp:PubChem_CID
|
4168
DB01233
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
restlessness
drowsiness
extrapyramidal symptoms
tardive dyskinesia
|
|
gptkbp:synonym
|
gptkb:Metoclopramid
gptkb:Metoclopramida
gptkb:Metoclopramidum
|
|
gptkbp:UNII
|
62H25DNH2L
|
|
gptkbp:usedFor
|
gptkb:gastroesophageal_reflux_disease
nausea
vomiting
gastroparesis
|
|
gptkbp:bfsParent
|
gptkb:Antiemetics
|
|
gptkbp:bfsLayer
|
6
|